Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed: An ideal prospective development study
Authors:
- 1 February 2015
- journal article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 14, 1-6
Abstract
Our aim was to evaluate the development of microbubble-enhanced sentinel lymph node (SLN) localization with placement of an I-125 seed in breast cancer patients as a potential alternative for SLN localization with nanocolloid. The study is conducted and reported following the IDEAL recommendations for evaluation of a new technique at Stage 2a (Prospective Development Study). Fourteen consecutive patients with 15 lesions underwent microbubble-enhanced SLN localization with placement of an I-125 seed after the standard SLN localization (nanocolloid). We placed an I-125 seed within or near the SLN following its identification using intradermally injected microbubbles. The SLN was excised guided by nanocolloid and the SLN containing the I-125 seed was searched for. All technical modifications are described and standardized outcomes measured. Twelve (80%) microbubble procedures with I-125 seed placements were technically successful. In three cases no microbubble-enhancing lymph node could be detected. Intraoperatively, we found nine I-125 seeds within 0.5 cm of the nanocolloid confirmed SLN. One I-125 seed was found next to a non-SLN and two I-125 seeds were not near any lymph node. Overall, the procedure was successful in 60% (9 out of 15) of the cases. Given the low success rate, we conclude that microbubble-enhanced SLN is not a viable alternative to the standard SLN procedure. Modifications to this technique did not improve its performance. Planned study (NTR3690 http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3690) was stopped early due to this conclusion and results reported in order to provide a full and transparent record of the evolution of technique.Keywords
This publication has 25 references indexed in Scilit:
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialThe Lancet Oncology, 2010
- Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissectionJournal of Surgical Oncology, 2010
- Micrometastases or Isolated Tumor Cells and the Outcome of Breast CancerNew England Journal of Medicine, 2009
- Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC TrialJNCI: Journal of the National Cancer Institute, 2006
- Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinomaCancer, 2005
- American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast CancerJournal of Clinical Oncology, 2005
- Lymphatic mapping and sentinel lymphadenectomy for breast cancerThe American Journal of Surgery, 2004
- A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast CancerNew England Journal of Medicine, 2003
- Credentialing issues with sentinel lymph node staging for breast cancerThe American Journal of Surgery, 2000
- Sentinel Lymph Node Biopsy in Breast Cancer: Guidelines and Pitfalls of Lymphoscintigraphy and Gamma Probe DetectionJournal of the American College of Surgeons, 1998